Compare Lennar Corporation (LEN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Lennar Corporation trades at $76.69 (market cap $18.44B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Lennar Corporation and Zimmer Biomet Holdings Inc are close in size by market cap, and Lennar Corporation pays the higher dividend (2.58%). Which is the better fit depends on your goals — on Pluang, investors hold Lennar Corporation for 67 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| LEN | ZBH | |
|---|---|---|
Market Cap | $18.44B | $16.95B |
Volume | 6,012,214 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $133.13 | $103.98 |
52-Week Low | $74.44 | $79.58 |
Typical Hold Time | 67 Days | 89 Days |
Enterprise Value | $22.86B | $24.02B |
Dividend Yield | 2.58% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LEN trades at $77.60, up 1.93% today, but faces a bearish technical outlook with recent earnings misses and declining profitability. Revenue fell to $34.19B in 2025 with net income margin dropping to 6.07%, while valuation ratios like P/E of 14.7 and P/B of 0.86 suggest potential undervaluation. Berkshire Hathaway's increased stake to 11.2% contrasts with analyst caution, as the stock hovers near support at $76 amid weak housing market sentiment.
The stock presents a value opportunity given low P/B and P/S ratios, but risks include persistent earnings underperformance, high mortgage rates pressuring housing demand, and allegations in a short report. Analyst consensus is mixed with a $77.38 price target, implying limited upside, while institutional buying by Berkshire signals long-term confidence amid near-term headwinds.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
